Very recently, FGF2 is found to be inhibited by the PI3K/Akt signaling pathway, which implies that the PI3K/Akt pathway and FGF2 might be potential therapeutic targets to treat tumor recurrence57. The gene discussed is AKT1; the disease is neoplasm.